X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glaxo: Consolidation hits 3QFY02 - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 25, 2001

    Glaxo: Consolidation hits 3QFY02

    Glaxo India has shown a sharp drop in sales and operating profit for the nine months ended FY02. The financials results for 9mFY02 are on a merged basis with Smithkline Beecham Pharma and hence not comparable. The approval has been effective with retrospective effect from Jan 1' 2001.

    (Rs m) 9mFY01 9mFY02 %Change 3QFY01 3QFY02 %Change
    Sales 6,822 6,762 -0.9% 2,122 2,835 33.6%
    Other Income 262 223 -15.0% 101 76 -25.0%
    Expenditure 6,162 6,179 0.3% 1,918 2,548 32.9%
    Operating Profit (EBDIT) 661 583 -11.8% 205 288 40.4%
    Operating Profit Margin (%) 9.7% 8.6%   9.6% 10.1%  
    Interest 73 71 -1.8% 26 29 11.1%
    Depreciation 119 126 6.2% 42 53 26.7%
    Profit before Tax 731 608 -16.8% 238 282 18.3%
    Extraordinary Income 155 394        
    Tax 297 294 -1.0% 85 101 18.8%
    Profit after Tax/(Loss) 589 708 20.1% 153 181 18.0%
    Net profit margin (%) 8.6% 10.5%   7.2% 6.4%  
    No. of Shares (eoy) (m) 60 60   60 60  
    Diluted Earnings per share* 13.1 15.8   10.2 12.1  
    P/E (at current price) 16.0   20.9  
    (*- annualised)            

    To make the results more comparable we have added the nine months results of Glaxo and SmithKline Pharma on a line to line basis. On a comparative basis, the merged entity recorded a drop in revenues by around 12%. PBT has fallen more sharply by around 36%. The drop in sales could be attributed to discontinuance of several brands by Glaxo and drop in revenues from vaccines business in case of SmithKline Pharma.

    Merged numbers YoY
      9mFY01 9mFY02 %Change
    Sales 9,242 8,073 -12.6%
    PBT 1,167 742 -36.4%
    Net profit 788 784 -0.5%

    Expenses for 9 months ended 30th September'01 include VRS costs (till date) and restructuring costs totalling Rs 181.8 m. A VRS for the company's factory at Worli, Mumbai is currently on and is expected to cost the company an additional sum of Rs 750 m. Glaxo's profitability was also affected due to higher provision for taxation in view of the new policy on deferred taxation.

    Except an overlap in vitamins segment, Glaxo’s product portfolio is complimentary with that of SmithKline Pharma. While Glaxo has strong presence in Vitamins and Dermatology segments, SmithKline Pharma is increasing its focus on vaccines segment. The merged entity would have a wider product portfolio across various therapeutic segments. A wider basket of products enables cross selling of products to the same set of doctors and physicians.

    The merger is also expected to create considerable operational cost savings. The cumulative cost savings are estimated to be in the range of Rs 470 m by FY03. The primary areas for cost savings would be bulk sourcing of raw materials, reduction in staff costs and shift from high cost manufacturing centers. The merger effect coupled with Glaxo’s focus on strategic brands is expected to result in operating margins improvement. The company has also launched several new products in the last one year.

    The markets would be closely watching the results of current restructuring exercise and benefits emerging from operational synergies with SmithKline Pharma. In the long run however, the company’s growth would depend on the new parent’s commitment towards GSK India in terms of new product introductions. Though usual concerns over 100% subsidiary are subdued in case of Glaxo at this point of time, the parent company does have a subsidiary operating in India viz, SmithKline Beecham Asia Pvt. Ltd.

    Currently, both Glaxo and SmithKline are trading seperately at Rs 254 and Rs 124 respectively, reflecting the swap ratio of 2:1. We expect the merged entity to record a net profit of around Rs 906 m for FY02 which translates into an EPS of Rs 12.2 for the current year.

     

     

    Equitymaster requests your view! Post a comment on "Glaxo: Consolidation hits 3QFY02". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    GSK PHARMA SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK GSK PHARMA

    • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    GSK PHARMA 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE GSK PHARMA WITH

    MARKET STATS